Abstract
Catheter-based micro-axial ventricular assist device Impella® (Abiomed, Danvers, MA) has been used in Japanese patients with drug-refractory acute heart failure (AHF) since 2017. This is the first interim analysis of the ongoing Japan Registry for Percutaneous Ventricular Assist Device (J-PVAD) to investigate the safety and efficacy of Impella support. Between October 2017 and January 2020, 823 Japanese patients, who were treated with the Impella 2.5, CP, or 5.0 pump, were enrolled. The primary endpoints were safety profiles and cumulative 30-day survival. Among them, 44.8% of patients were acute myocardial infarction with cardiogenic shock. The Impella pumps were unable to implant in 4 patients. The Impella 2.5, CP, and 5.0 pumps were used in 72.4%, 6.2%, and 16.6%, respectively, and mean support duration was 8.1 ± 10.2 days. Combination use of Impella and venoarterial extracorporeal membrane oxygenation (VA-ECMO) was applied for 387 patients (47.3%). Pump stop occurred 22 patients (2.7%). Major adverse events included hemolysis (11.2%), hemorrhage/hematoma (6.1%), peripheral ischemia (1.6%), and stroke (1.6%). The overall 30-day survival was 62.2%. Survival of patients with single Impella support was significantly higher than patients with Impella combined with VA-ECMO support (81.1% vs 49.6%; p < 0.01), who had lower blood pressure, lower left ventricular ejection fraction, and higher degree of inotropic support. Results suggest that short-term outcome of Impella support for Japanese patients was favorable with acceptable safety profiles.
Similar content being viewed by others
References
Okura Y, Ramadan MM, Ohno Y, Mitsuma W, Tanaka K, Ito M, Suzuki K, Tanabe N, Kodama M, Aizawa Y. Impending epidemic: future projection of heart failure in Japan to the year 2055. Circ J. 2008;72:489–91.
Shiba N, Watanabe J, Shinozaki T, Koseki Y, Sakuma M, Kagaya Y, Shirato K, Investigators C. Analysis of chronic heart failure registry in the Tohoku district: third year follow-up. Circ J. 2004;68:427–34.
Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3:7–11.
Nagai T, Sundaram V, Rothnie K, Quint JK, Shoaib A, Shiraishi Y, Kohsaka S, Piper S, McDonagh TA, Hardman SMC, Goda A, Mizuno A, Kohno T, Rigby AS, Yoshikawa T, Clark AL, Anzai T, Cleland JGF. Mortality after admission for heart failure in the UK compared with Japan. Open Heart. 2018;5: e000811.
Ueki Y, Mohri M, Matoba T, Tsujita Y, Yamasaki M, Tachibana E, Yonemoto N, Nagao K. Characteristics and predictors of mortality in patients with cardiovascular shock in japan- results from the japanese circulation society cardiovascular shock registry. Circ J. 2016;80:852–9.
Shaefi S, O’Gara B, Kociol RD, Joynt K, Mueller A, Nizamuddin J, Mahmood E, Talmor D, Shahul S. Effect of cardiogenic shock hospital volume on mortality in patients with cardiogenic shock. J Am Heart Assoc. 2015;4: e001462.
Thiele H, Zeymer U, Thelemann N, Neumann FJ, Hausleiter J, Abdel-Wahab M, Meyer-Saraei R, Fuernau G, Eitel I, Hambrecht R, Bohm M, Werdan K, Felix SB, Hennersdorf M, Schneider S, Ouarrak T, Desch S, de Waha-Thiele S, Investigators IIT. Intraaortic balloon pump in cardiogenic shock complicating acute myocardial infarction: long-term 6-year outcome of the randomized IABP-shock II trial. Circulation. 2018. https://doi.org/10.1161/CIRCULATIONAHA.118.038201.
Yoshida S, Toda K, Miyagawa S, Yoshikawa Y, Hata H, Torikai K, Shimamura K, Saito S, Kin K, Maeda K, Domae K, Watanabe Y, Matsuura R, Masada K, Hikoso S, Mizote I, Sera F, Nakamoto K, Masawa T, Sakata Y, Kuratani T, Sawa Y. Impella 5.0 as a bridge to implantable left ventricular assist device- first clinical case in Japan. Circ J. 2018;82:2923–4.
Lauridsen MD, Rorth R, Lindholm MG, Kjaergaard J, Schmidt M, Moller JE, Hassager C, Torp-Pedersen C, Gislason G, Kober L, Fosbol EL. Trends in first-time hospitalization, management, and short-term mortality in acute myocardial infarction-related cardiogenic shock from 2005 to 2017: A nationwide cohort study. Am Heart J. 2020;229:127–37.
Thiagarajan RR, Barbaro RP, Rycus PT, McMullan DM, Conrad SA, Fortenberry JD, Paden ML, and centers. Extracorporeal life support organization registry international report 2016. ASAIO J. 2017;63:60–7.
Pappalardo F, Schulte C, Pieri M, Schrage B, Contri R, Soeffker G, Greco T, Lembo R, Mullerleile K, Colombo A, Sydow K, De Bonis M, Wagner F, Reichenspurner H, Blankenberg S, Zangrillo A, Westermann D. Concomitant implantation of Impella((R)) on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock. Eur J Heart Fail. 2017;19:404–12.
Patel SM, Lipinski J, Al-Kindi SG, Patel T, Saric P, Li J, Nadeem F, Ladas T, Alaiti A, Phillips A, Medalion B, Deo S, Elgudin Y, Costa MA, Osman MN, Attizzani GF, Oliveira GH, Sareyyupoglu B, Bezerra HG. Simultaneous venoarterial extracorporeal membrane oxygenation and percutaneous left ventricular decompression therapy with impella is associated with improved outcomes in refractory cardiogenic shock. ASAIO J. 2019;65:21–8.
Nakamura M, Imamura T, Fukui T, Hori M, Ueno Y, Uen H, Kinugawa K. Impact of the angle between aortic and mitral annulus on the occurrence of hemolysis during Impella support. J Artif Organs. 2020;23:207–13.
Roberts N, Chandrasekaran U, Das S, Qi Z, Corbett S. Hemolysis associated with Impella heart pump positioning: In vitro hemolysis testing and computational fluid dynamics modeling. Int J Artif Organs. 2020. https://doi.org/10.1177/0391398820909843.
Flierl U, Tongers J, Berliner D, Sieweke JT, Zauner F, Wingert C, Riehle C, Bauersachs J, Schafer A. Acquired von Willebrand syndrome in cardiogenic shock patients on mechanical circulatory microaxial pump support. PLoS One. 2017;12: e0183193.
Baumann Kreuziger L, Massicotte MP. Mechanical circulatory support: balancing bleeding and clotting in high-risk patients. Hematology Am Soc Hematol Educ Program. 2015;2015:61–8.
Massicotte MP, Maul TM, Snyder TA, Baumann KL. Mechanical circulatory support and antithrombotic therapy: looking for the holy grail. ASAIO J. 2017;63:1–4.
Toda K, Sawa Y. Intraaortic balloon pumping (IABP) and impella. Kyobu Geka. 2018;71:821–6.
Acknowledgements
A part of the current study was presented at 84th Annual Scientific Meeting of the Japanese Circulation Society, Late Breaking Session. IRB information: “Catheter-type ventricular assist device registry study”, Graduate School of Medicine/Faculty of Medicine, Osaka University Ethics Committee, Approval #17232
Funding
This study was partially funded by Japan Abiomed Post-Market Surveillance Program.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of interest
No conflict interest of authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Toda, K., Ako, J., Hirayama, A. et al. Three-year experience of catheter-based micro-axial left ventricular assist device, Impella, in Japanese patients: the first interim analysis of Japan registry for percutaneous ventricular assist device (J-PVAD). J Artif Organs 26, 17–23 (2023). https://doi.org/10.1007/s10047-022-01328-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10047-022-01328-1